Evidence map›Paper›PMID 28241036›Full record

ArticlePLoS neglected tropical diseases2017

Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression.

Norman Nausch, Daniel Antwi-Berko, Yusif Mubarik, Kabiru Mohammed Abass, Wellington Owusu, Ellis Owusu-Dabo, Linda Batsa Debrah, Alexander Yaw Debrah, Marc Jacobsen, Richard O Phillips

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Buruli ulcer.Nature reviews. Disease primers · 2025
    Review
  4. Article
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Norman NauschPediatric Pneumology and Infectious Diseases Group, Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich-Heine University, Dusseldorf, Germany.ORCID 0000-0002-9704-2148
Daniel Antwi-BerkoKumasi Centre for Collaborative Research in Tropical Medicine, KNUST, Kumasi, Ghana.
Yusif MubarikKumasi Centre for Collaborative Research in Tropical Medicine, KNUST, Kumasi, Ghana.
Kabiru Mohammed AbassAgogo Presbyterian Hospital, Agogo, Ghana.
Wellington OwusuKumasi Centre for Collaborative Research in Tropical Medicine, KNUST, Kumasi, Ghana.
Ellis Owusu-DaboKumasi Centre for Collaborative Research in Tropical Medicine, KNUST, Kumasi, Ghana.
Linda Batsa DebrahKumasi Centre for Collaborative Research in Tropical Medicine, KNUST, Kumasi, Ghana.
Alexander Yaw DebrahKumasi Centre for Collaborative Research in Tropical Medicine, KNUST, Kumasi, Ghana.
Marc JacobsenPediatric Pneumology and Infectious Diseases Group, Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich-Heine University, Dusseldorf, Germany.
Richard O PhillipsKumasi Centre for Collaborative Research in Tropical Medicine, KNUST, Kumasi, Ghana.
Kwame Nkrumah University of Science and Technology · GHDüsseldorf University Hospital · DEPresbyterian University, Ghana · GH

Funding

Medical Research Council MR/J01477X/1
6 · The paper itself

Abstract

backgroundBuruli ulcer disease (BUD), caused by Mycobacterium (M.) ulcerans, is the third most common mycobacterial disease after tuberculosis and leprosy. BUD causes necrotic skin lesions and is a significant problem for health care in the affected countries. As for other mycobacterial infections, T cell mediated immune responses are important for protection and recovery during treatment, but detailed studies investigating these immune responses in BUD patients are scarce. In this study, we aimed to characterise M. ulcerans-specific CD4+ T cell responses in BUD patients and to analyse specific cytokine-producing T cells in the context of disease severity and progression. METHODOLOGY/PRINCIPAL

findingsFor this case-control study, whole blood samples of BUD patients (N = 36, 1.5-17 years of age) and healthy contacts (N = 22, 3-15 years of age) were stimulated with antigen prepared from M. ulcerans and CD4+ T cells were analysed for the expression of TNFα, IFNγ and CD40L by flow cytometry. The proportions and profile of cytokine producing CD4+ T cells was compared between the two study groups and correlated with disease progression and severity. Proportions of cytokine double-positive IFNγ+TNFα+, TNFα+CD40L+, IFNγ+CD40L+ (p = 0.014, p = 0.010, p = 0.002, respectively) and triple positive IFNγ+TNFα+CD40L+ (p = 0.010) producing CD4+ T cell subsets were increased in BUD patients. In addition, TNFα+CD40L-IFNγ- CD4+ T cells differed between patients and controls (p = 0.034). TNFα+CD40L-IFNγ- CD4+ T cells were correlated with lesion size (p = 0.010) and proportion were higher in 'slow' healers compared to 'fast healers' (p = 0.030).

conclusionsWe were able to identify M. ulcerans-specific CD4+ T cell subsets with specific cytokine profiles. In particular a CD4+ T cell subset, producing TNFα but not IFNγ and CD40L, showed association with lesion size and healing progress. Further studies are required to investigate, if the identified CD4+ T cell subset has the potential to be used as biomarker for diagnosis, severity and/or progression of disease.

Indexed as

AdolescentBiomarkersBuruli UlcerCase-Control StudiesCD40 LigandCD4-Positive T-LymphocytesCells, CulturedChildChild, PreschoolCytokinesDisease ProgressionFemaleHumansInfantMaleMycobacterium ulceransBiomarkersCD40 LigandCytokines

Identifiers

PMID28241036
PMCPMC5344519
OpenAlexW2593459589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.